Amgen is adding an arrow to its anti-inflammatory quiver with its buyout of Seattle’s Rodeo Therapeutics. The deal will see just $55 million change hands upfront, but another $666 million could come into play if Rodeo’s assets live up to their hype.

Guess you can’t always go home again. The Federal Trade Commission (FTC) said it would intervene in Illumina’s $8 billion acquisition plans for its former spinout, the multi-cancer blood test developer Grail.

Wrap a major acquisition? Check. Go public? Check. Bring on a slew of experienced executives and directors, including a new CEO? Check. Next up for Butterfly Network: Expand, expand, expand.

Novartis is adding a group of radioligand therapies to its pipeline, just one week after its radioligand treatment for prostate cancer staved off cancer progression and helped patients live longer in a phase 3 study.

Forma Therapeutics has presented blinded data on sickle cell disease patients who received 600 mg of FT-4202. The high-dose cohort featured fewer hemoglobin responders than the 300-mg arm, but the safety profile offers encouragement for the ongoing phase 2/3 registrational trial.

When Kriya Therapeutics raised $80.5 million in a series A funding round last May, it was as clear a sign as any that gene therapy is moving beyond rare diseases and going mainstream. The biotech is working on three gene therapies to treat metabolic diseases, including its lead asset, KT-A112, for Type 1 diabetes.

Cancer drugs stop working when malignant cells develop molecular changes that allow them to evade the drugs’ effects. As a result, cancer treatment typically requires multiple phases, where patients start with the standard of care and then move onto second-, third-, or even fourth-line therapies as their cancer outsmarts each drug.  

Orphazyme saw its stock sink more than 30% in Europe Monday morning after it failed to to hit any of the endpoints in a phase 2/3 trial.

As light begins to shine at the end of the pandemic tunnel, drug manufacturers and healthcare systems are looking at the best ways to maintain the digital momentum spurred by the crisis to provide support to patients and overcome any barriers the transition to a post COVID-19 world may reveal.

Fed into a cancer patient’s bloodstream, millions of microscopic, radioactive glass beads migrate to a tumor and deliver a high-but-tailored dose of radiation. That’s the idea behind Boston Scientific’s TheraSphere treatment, approved by the FDA earlier this month, and a new study showed the therapy can do just that.